Información del artículo
Atazanavir (ATV) es un inhibidor de la proteasa (IP) del virus de la inmunodeficiencia humana (VIH) con alta actividad in vitro frente al VIH-1, que muestra una actividad aditiva en presencia de otros antirretrovirales y una actividad sinérgica con otros IP. Su absorción por vía oral es superior al 68%, alcanzándose la concentración máxima (Cmáx) aproximadamente 2-3 h después de su administración. Su absorción está relacionada con el pH gástrico, recomendándose su administración tras las comidas. La farmacocinética de ATV no es lineal; es decir, sus concentraciones plasmáticas (Cp) no aumentan en proporción con las dosis. ATV se une aproximadamente en un 86% a las proteínas plasmáticas. Su penetración en el líquido cefalorraquídeo, el semen o las secreciones genitales es variable, pero en general inferior al 10-20%. Su paso a través de la placenta, medido como la media de los cocientes entre las Cp en sangre de cordón umbilical respecto a las maternas, es de 0,13. El ATV es metabolizado mediante oxidación por las enzimas del citocromo P450, eliminándose con posterioridad por vía biliar en forma libre o glucuronidada (80%) y por la orina. Asimismo, es un inhibidor competitivo débil de la CYP3A4 y un fuerte inhibidor de la uridina difosfatoglucuronosiltransferasa 1A1, que es la causa de la frecuente hiperbilirrubinemia tras su administración y de sus interacciones farmacológicas.
Palabras clave:
Atazanavir
Farmacología
Farmacocinética
Atazanavir (ATV) is an HIV protease inhibitor (IP) with a high in vitro activity against HIV-1, that demonstrates a high additive activity in the presence of other antiretrovirals and a synergic activity with other PI. Oral absorption is greater than 68%, maximum concentration (Cmax) being reached approximately 2 to 3 h after its administration. Its absorption is dependent on gastric pH, its administration being recommended after meals. The pharmacokinetics (PK) of ATV are non-linear; that is to say, its plasma concentrations (Cp) do not increase in proportion to the dose. ATV is approximately 86% bound to plasma proteins. Its entry into the cerebrospinal fluid, semen or genital secretions varies but is generally less than 10-20%. Its passage across the placenta, measured as the mean of the ratios between the Cp in umbilical cord and maternal blood, is 0.13. ATV is metabolised by oxidation by cytochrome P450 enzymes, subsequently being eliminated by the bile duct in the free or glucuronide form (80%) and by the urine. ATV is a weak competitive inhibitor of CYP3A4 and a strong inhibitor of uridine diphosphate-glucuronosyltransferase 1A1, which is the cause of the frequent high plasma bilirubin after its administration and of its pharmacological interactions.
Key words:
Atazanavir
Pharmacology
Pharmacokinetics
El Texto completo está disponible en PDF
Bibliografía
[1.]
Reyataz. Ficha técnica del producto, 2008. European Medicines Agency. Disponible en: http://www.emea.europa.eu/humandocs/Humans/EPAR/reyataz/reyataz.htm.
[2.]
B.S. Robinson, K.A. Riccardi, Y.F. Gong, Q. Guo, D.A. Stock, W.S. Blair, et al.
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
Antimicrob Agents Chemother, 44 (2000), pp. 2093-2099
[3.]
E. Dam, S. Lebel-Binay, S. Rochas, L. Thibaut, J.L. Faudon, C.M. Thomas, et al.
Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Antivir Ther, 12 (2007), pp. 371-380
[4.]
L. Zhu, M. Liao, H. Chil, H. Sevinsky, T. Eley, Y. Wang, et al.
CASTLE study: Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment naive subjects.
New Orleans: 9th International Workshop on Clinical Pharmacology of HIV Therapy,
[5.]
G.L. Drusano, J.A. Bilello, S.L. Preston, E. O’Mara, S. Kaul, S. Schnittman, et al.
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
J Infect Dis, 183 (2001), pp. 1126-1129
[6.]
M. O’Mara, J. Smith, S.J. Olsen, T. Tanner, A.E. Schuster, S. Kaul.
BMS-232632: single oral dose safety and pharmacokinetic study in healthy volunteers.
38th Interscience Conference on Antimi crobial Agents and Chemotherapy,
[7.]
D. Randall, S. Agarwala, V. Mummanemi, et al.
Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies.
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy,
[8.]
S. Colombo, T. Buclin, M. Cavassini, L.A. Décosterd, A. Telenti, J. Biollaz, et al.
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Atimicrob Agents Chemother, 50 (2006), pp. 3801-3808
[9.]
Randall D, Agarwala S, Mummanemi V, et al. Tissue compartment concentrations of atazanavir in cerebrospinal fluid, semial fluid and plasma in HIV+ subjects. 42nd Abstract n.° H-1711.
[10.]
E. Van Leeuwen, R. Ter Heine, F. Van der Veen, S. Repping, J.H. Beijnen, J.M. Prins.
Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
Antimicrob Agents Chemother, 51 (2007), pp. 335-337
[11.]
J.B. Dumond, R.F. Yeh, K.B. Patterson, A.H. Corbett, B.H. Jung, N.L. Rezk, et al.
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
AIDS, 21 (2007), pp. 1899-1907
[12.]
D. Ripamonti, D. Cattaneo, F. Maggiolo, M. Airoldi, L. Frigerio, P. Bertuletti, et al.
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
AIDS, 21 (2007), pp. 2409-2415
[13.]
C. Le Tiec, A. Barrail, C. Goujard, A.M. Taburet.
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Clin Pharmacokinet, 44 (2005), pp. 1035-1050
[14.]
J. Ford, M. Boffito, D. Maitland, A. Hill, D. Back, S. Khoo, et al.
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
J Antimicrob Chemother, 58 (2006), pp. 1009-1016
[15.]
Reyataz. Scientific discussion. European Medicines Agency. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/reyataz/586503en6.pdf
[16.]
Reyataz. Full Prescribing Information. US Food and Drug Administration. 2008. Disponible en: http://www.fda.gov/cder/foi/label/2008/021567s015lbl.pdf
[17.]
E. O’Mara, D. Randall, R. Stoltz, M. Geraldes, V. Mummaneni.
BMS-232632: a prospective study of age and gender effects on the single-dose pharmacokinetics in healthy volunteers.
1st International AIDS Society Conference,
[18.]
Von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1- infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008; Advance Access published on May 13, 2008.
[19.]
E. O’Mara, P. Piliero, G. Drusano, V. Mummaneni, S. Preston, A. Schuster, et al.
BMS-232632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor-naive HIV+ population [abstract P9].
AIDS, 14 (2000), pp. S19
[20.]
J.E. Ray, D. Marriott, M.T. Bloch, A.J. McLachlan.
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.
Br J Clin Pharmacol, 60 (2005), pp. 291-299
[21.]
D.E. Smith, S. Jeganathan, J. Ray.
Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.
HIV Clin Trials, 7 (2006), pp. 34-38
[22.]
J. Moltó, J.R. Santos, M. Valle, C. Miranda, J. Miranda, A. Blanco, et al.
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Ther Drug Monit, 29 (2007), pp. 648-651
[23.]
J.M. Poirier, J. Guiard-Schmid, J. Meynard, et al.
Atazanavir (ATV) plasma concentrations in HIV-infected patients treated with 400 mg ATV or ritonavir boosted ATV (300/100 mg) qd in clinical practice.
7th International Workshop on Clinical Pharmacology of HIV Therapy,
[24.]
R. Bertz, Y. Wang, L. Mahnke, A. Persson, E. Chung, M. Mathew, et al.
Assessment of Pharmacokinetic/Pharmacodynamic Relationships through 48 Weeks from a Study in HIV+, ART-naive Subjects Receiving Antiretroviral Regimens Containing Atazanavir 400 mg or Atazanavir/Ritonavir 300/100 mg Once Daily.
14th Conference on Retroviruses and Opportunistic Infections,
[25.]
A. Winston, M. Bloch, A. Carr, J. Amin, P.W. Mallon, J. Ray, et al.
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
J Antimicrob Chemother, 56 (2005), pp. 380-387
[26.]
R.M. Cleijsen, M.E. Van de Ende, F.P. Kroon, F.V. Lunel, P.P. Koopmans, L. Gras, et al.
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
J Antimicrob Chemother, 60 (2007), pp. 897-900
[27.]
S. Bonora, A. D’Avolio, C. Tettoni, et al.
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients.
9th International Workshop on Clinical Pharmacology of HIV Therapy,
[28.]
J.R. King, H. Wynn, R. Brundage, E.P. Acosta.
Pharmacokinetic enhancement of protease inhibitor therapy.
Clin Pharmacokinet, 43 (2004), pp. 291-310
[29.]
S. Agarwala, R. Russo, V. Mummaneni, D. Randall, M. Geraldes, E. O’Mara.
Steady-State Pharmacokinetic (PK) Interaction Study of Atazanavir (ATV) with Ritonavir (RTV) in Healthy Subjects.
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy,
[30.]
A.M. Taburet, C. Piketty, C. Chazallon, I. Vincent, L. Gérard, V. Calvez, et al.
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother, 48 (2004), pp. 2091-2096
[31.]
I. Pellegrin, D. Breilh, J.M. Ragnaud, S. Boucher, D. Neau, H. Fleury, et al.
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Antivir Ther, 11 (2006), pp. 421-429
[32.]
S. Rodríguez-Nóvoa, L. Martín-Carbonero, P. Barreiro, G. González-Pardo, I. Jiménez- Nácher, J. González-Lahoz, et al.
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
AIDS, 21 (2007), pp. 41-46
[33.]
S. Di Giambenedetto, A. De Luca, P. Villani, A. Bacarelli, E. Ragazzoni, M. Regazzi, et al.
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
HIV Med, 9 (2008), pp. 239-245
[34.]
D. Gonzalez de Requena, S. Bonora, F. Canta, R. Marrone, A. D’Avolio, M. Sciandra, et al.
Atazanavir trough is associated with efficacy and safety: definition of therapeutic range.
12th Conference on Retroviruses and Opportunistic Infections,
[35.]
Optimizing TDM in HIV clinical care. 2003. Disponible en: http://www.hivpharmacology.com.
[36.]
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [accedido Ene 08]. Disponible en: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
[37.]
S. Agarwala, T. Eley, M. Child, A. Persson, D. Filoramo, X. Xu, et al.
Pharmacokinetics of Atazanavir in severely renally impaired subjects including those on hemodialysis.
8th International Workshop on Clinical Pharmacology of HIV Therapy,
[38.]
P. Barreiro, S. Rodríguez-Novoa, P. Labarga, A. Ruiz, I. Jiménez-Nácher, L. Martín-Carbonero, et al.
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
J Infect Dis, 195 (2007), pp. 973-979
[39.]
M. Natha, P. Hay, G. Taylor, C. Wood, L. Sarner, L. Cunningham, et al.
Atazanavir Use in Pregnancy: a report of 33 cases.
14th Conference on Retroviruses and Opportunistic Infections,
[40.]
D. Ripamonti, D. Cattaneo, F. Maggiolo, M. Airoldi, L. Frigerio, P. Bertuletti, et al.
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
AIDS, 21 (2007), pp. 2409-2415
[41.]
S. Agarwala, K. Gray, T. Elay, et al.
Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects.
3rd Internation al AIDS Society Conference on HIV Pathogenesis and Treatmen,
[42.]
D.L. Tomilo, P.F. Smith, A.B. Ogundele, R. Difrancesco, C.S. Berenson, E. Eberhardt, et al.
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Pharmacotherapy, 26 (2006), pp. 341-346
[43.]
A.D. Luber, R. Brower, D. Kim, R. Silverman, C.A. Peloquin, I. Frank.
Steadystate pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
HIV Med, 8 (2007), pp. 457-464
[44.]
J.J. Kiser, K.A. Lichtenstein, P.L. Anderson, C.V. Fletcher.
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
Pharmacotherapy, 26 (2006), pp. 511-514
[45.]
S. Agarwala, A. Persson, M. Eley, et al.
Effect of famotidine 20 and 40mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects.
14th Conference on Retrovirus and Opportunistic Infections,
[46.]
J.B. Guiard-Schmid, J.M. Poirier, P. Bonnard, J.L. Meynard, L. Slama, T. Lukiana, et al.
Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.
AIDS, 19 (2005), pp. 1937-1938
[47.]
E.G. Sahloff, J.M. Duggan.
Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
Ann Pharmacother, 40 (2006), pp. 1731-1736
[48.]
K.M. Chan-Tack, A. Edozien.
Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
Clin Infect Dis, 42 (2006), pp. 1344
[49.]
K.J. Furtek, N.F. Crum, P.E. Olson, M.R. Wallace.
Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?.
J Acquir Immune Defic Syndr, 41 (2006), pp. 394-396
[50.]
D.M. Burger, S. Agarwala, M. Child, A. Been-Tiktak, Y. Wang, R. Bertz.
Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
Antimicrob Agents Chemother, 50 (2006), pp. 3336-3342
[51.]
J. Mallolas, M. Sarasa, M. Nomdedeu, A. Soriano, Y. López-Púa, J.L. Blanco, et al.
Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
HIV Med, 8 (2007), pp. 131-134
[52.]
E.P. Acosta, M.A. Kendall, J.G. Gerber, B. Alston-Smith, S.L. Koletar, A.R. Zolopa, et al.
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
Antimicrob Agents Chemother, 51 (2007), pp. 3104-3110
[53.]
S. Agarwala, V. Mummaneni, D. Randall, M. Geraldes, R. Stoltz, E. O’Mara.
Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects.
9th Conference on Retroviruses and Opportunistic Infections,
[54.]
S. Preston, P. Piliero, E. O’Mara, et al.
Evaluation of steady-state interaction between atazanavir and efavirenz.
9th Conference on Retroviruses and Opportunistic Infections,
[55.]
E. Dailly, O. Tribut, P. Tattevin, C. Arvieux, P. Perré, F. Raffi, et al.
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Eur J Clin Pharmacol, 62 (2006), pp. 523-526
[56.]
M. Schöller-Gyüre, B. Woodfall, T. De Marez, et al.
Pharmacokinetics of TMC125, with atazanavir and atazanavir/ritonavir.
46thInterscience Conference on Antimicrobial Agents and Chemotherapy,
[57.]
S. Kaul, K. Bassi, B. Damle, J. Xie, J. Gale, B. Kearne, et al.
Pharmacokinetic Evaluation of the Combination of Atazanavir, Enteric Coated Didanosine, and Tenofovir Disoproxil Fumarate for a Once-Daily Antiretroviral Regimen.
43th Interscience Conference on Antimicrobial Agents and Chemotherapy,
[58.]
A.M. Taburet, C. Piketty, C. Chazallon, I. Vincent, L. Gérard, V. Calvez, et al.
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother, 48 (2004), pp. 2091-2096
[59.]
N. Von Hentig, B. Dauer, A. Haberl, S. Klauke, T. Lutz, S. Staszewski, et al.
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Eur J Clin Pharmacol, 63 (2007), pp. 935-940
[60.]
G. Friedland, L. Andrews, T. Schreibman, S. Agarwala, L. Daley, M. Child, et al.
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.
AIDS, 19 (2005), pp. 1635-1641
[61.]
N. Von Hentig, A. Müller, C. Rottmann, T. Wolf, T. Lutz, S. Klauke, et al.
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
Antimicrob Agents Chemother, 51 (2007), pp. 1431-1439
[62.]
E. Ribera, C. Azuaje, R.M. Lopez, M. Diaz, M. Feijoo, L. Pou, et al.
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
AIDS, 20 (2006), pp. 1131-1139
[63.]
Raltegravir. Ficha técnica del producto. 2008. European Medicines Agency. Disponible en: http://www.emea.europa.eu/humandocs/Humans/EPAR/isentress/ isentress.htm
[64.]
S. Abel, D. Russell, R.J. Taylor-Worth, C.E. Ridgway, G.J. Muirhead.
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Br J Clin Pharmacol, 65 (2008), pp. 27-37
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
